ARS Pharmaceuticals 将来の成長

Future 基準チェック /56

ARS Pharmaceuticalsは、60.4%と39.2%でそれぞれ年率60.4%で利益と収益が成長すると予測される一方、EPSはgrowで60.7%年率。

主要情報

60.4%

収益成長率

60.72%

EPS成長率

Biotechs 収益成長	23.9%
収益成長率	39.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	25 Nov 2025

今後の成長に関する最新情報

Recent updates

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

Nov 10

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Aug 28

ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Aug 15

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jun 30

Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%

May 15

80% Coverage And Pediatric Launch Will Expand Global Markets

May 01 Rapid payer coverage expansion and pediatric market entry may enhance revenue and ease prescribing burdens with reduced authorization requirements.

Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%

Apr 03

Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term

Mar 26

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Feb 06

ARS Pharmaceuticals: Demand Curve Is Key Unknown

Nov 20

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12

業績と収益の成長予測

NasdaqGM:SPRY - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	307	-36	-10	-54	5
12/31/2026	183	-132	-82	-107	6
12/31/2025	82	-173	-193	-141	6
9/30/2025	143	-80	-94	-85	N/A
6/30/2025	112	-48	-61	-53	N/A
3/31/2025	97	-16	-29	-20	N/A
12/31/2024	89	8	5	14	N/A
9/30/2024	3	-49	-46	-46	N/A
6/30/2024	1	-45	-44	-44	N/A
3/31/2024	0	-50	-54	-54	N/A
12/31/2023	0	-54	-59	-59	N/A
9/30/2023	0	-62	-63	-62	N/A
6/30/2023	0	-53	-56	-55	N/A
3/31/2023	1	-42	-46	-46	N/A
12/31/2022	1	-35	-40	-40	N/A
9/30/2022	2	-25	-25	-25	N/A
6/30/2022	2	-25	-24	-24	N/A
3/31/2022	4	-23	-21	-21	N/A
12/31/2021	6	-20	-18	-18	N/A
12/31/2020	18	-1	9	9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SPRYは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 3.3% ) よりも高い成長率であると考えられます。

収益対市場: SPRY今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: SPRY今後 3 年以内に収益を上げることが予想されます。

収益対市場: SPRYの収益 ( 39.2% ) US市場 ( 10.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: SPRYの収益 ( 39.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SPRYの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/12/24 16:35
終値	2025/12/24 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

ARS Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。11

アナリスト	機関
Joshua Schimmer	Cantor Fitzgerald & Co.
Roanna Clarissa Ruiz	Leerink Partners LLC
Andreas Argyrides	Oppenheimer & Co. Inc.

ARS Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus revenue estimates decrease by 25%

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.64 loss

Consensus revenue estimates decrease by 99%, EPS upgraded

Consensus revenue estimates fall by 67%

Recent updates

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

ARS Pharmaceuticals, Inc. announced that it expects to receive $250 million in funding

ARS Pharmaceuticals, Inc. Announces Approval for Neffy®? (epinephrine Nasal Spray) for the Emergency Treatment of Allergic Reactions

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

AARS Pharmaceuticals, Inc. Announces Approval of EURneffy®? (Adrenaline Nasal Spray) for the Emergency Treatment of Allergic Reactions

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Growth Index

Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%

ARS Pharmaceuticals, Inc.'s Neffy (epinephrine Nasal Spray) 1 mg Is Now Available in the United States for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

80% Coverage And Pediatric Launch Will Expand Global Markets

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2025

Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%

Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term

ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals, Inc. Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals, Inc. Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals Announces Filings for Approval of Neffy in China, Japan and Australia

ARS Pharmaceuticals: Demand Curve Is Key Unknown

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

ARS Pharmaceuticals, Inc. Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Approval of EURneffy (adrenaline nasal spray) in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index

ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)

Consensus revenue estimates decrease by 19%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study

New minor risk - Profitability

Consensus revenue estimates decrease by 25%

Forecast to breakeven in 2026

ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Consensus EPS estimates upgraded to US$0.64 loss

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2022)

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Consensus revenue estimates decrease by 99%, EPS upgraded

ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2022)

Consensus revenue estimates fall by 67%

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1Q 2022)

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Chief Financial Officer recently bought US$52k worth of stock

No independent directors

ARS Pharmaceuticals, Inc. Announces Presentation of Clinical Data Supporting Neffy® for the Treatment of Allergic Reactions (Type I) Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Board Changes